Categories
Suven Life Sciences Limited — Updates, 12-05-2026: Press Release
12-05-2026 · 03:05 pm
Suven Life Sciences hit 76% enrollment in its Phase 3 Masupirdine trial for Alzheimer's agitation. Patient enrollment is accelerating, with completion targeted by end-2026 and data readout expected by April 2027. Positive progress for a potential new treatment.
No comments yet. Be the first to comment!